Definitive Contract HHSN261201500035C
Award Date
9/22/15
Potential Completion Date
8/15/16
Potential Value
$298K
Federal Agency
National Cancer Institute
Awardee
Pgxl Technologies LLC
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Louisville, KY 40202, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
27
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $299,654 firm fixed price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Pgxl Technologies LLC, a minority-owned limited liability company. The contract, titled "DETECTION, ISOLATION, AND ANALYSIS OF SINGLE CTCS," has a completion date of September 12, 2014 and does not appear to have a set-aside designation. The contract is for the detection, isolation, and analysis of single circulating tumor cells (CTCs). Pgxl Technologies LLC is the...
This is a federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pointcare Genomics Corp, a small minority-owned business, for research and development in biomedical basic research. The contract is a definitive, firm-fixed price contract valued at $299,961.00 and is part of the SBIR (Small Business Innovation Research) Program Phase I. The contract has a total small business set-aside designation and was awarded on September 22, 2015, with a completion date of...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Personal Genome Diagnostics Inc., a for-profit company that provides molecular tissue testing services to federal agencies. The contract has a ceiling value of $222,994.00 and is a firm-fixed-price definitive contract for the development of a non-invasive approach to assess mutation load in tumors for treatment with...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
This federal contract award was made by the National Cancer Institute (NCI), a civilian agency, to Akrivis Technologies, LLC, a minority-owned, small disadvantaged business. The $224,452 firm-fixed-price definitive contract was awarded on September 12, 2014, with a period of performance ending on June 30, 2015. The contract was not set aside for any special designation. Based on the information provided, this award appears to be for a standalone contract rather than associated with a larger...
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.</p>
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase 2 contract worth $299,920.00 to Akrivis Technologies, LLC, a minority-owned, small disadvantaged business in Cambridge, MA. The contract, which is a definitive, firm-fixed-price contract, supports SBIR Topic 314 and has an ultimate completion date of October 21, 2016. The contract is set aside for total small business participation.</p>
The National Cancer Institute awarded a $224,997.00 firm fixed-price definitive contract to Paganini Biopharma, Inc. for research and development in biomedical basic research. The contract has a performance period ending on September 17, 2015 and was awarded on September 18, 2014. This contract was not set aside for any specific business type. The National Cancer Institute is a civilian agency within the U.S. Department of Health and Human Services that conducts and supports cancer research.